Pro Medicus (ASX:PME), the Melbourne-founded radiology software company that has quietly become one of the ASX's most expensive and most watched growth stocks, delivered a full-year result on Tuesday 18 August 2026 that ticked almost every box the market wanted: record revenue, fatter margins, a bigger dividend, a swelling forward order book and another clutch of long-dated contracts with US health systems. The shares responded in kind, rallying strongly through the session after the company reported the year to 30 June.

There is, however, a wrinkle worth untangling before the champagne. The eye-catching line that group net profit "more than doubled" to $265.3 million is technically accurate but flatters the underlying engine. A large slice of that figure came not from selling software but from mark-to-market gains on the company's Investment portfolio. Strip those out and the operating story is still very good — just not double.

What happened

Pro Medicus lodged its FY26 results with the ASX before the open, reporting Revenue of $261.7 million, up 22.9% on the prior year. Reported net profit after tax landed at $265.3 million, a headline gain of 130.3%. The board declared a fully franked final Dividend of 37.0 cents per share, lifting the full-year payout to 69.0 cents (including the 32.0-cent interim), up from 55.0 cents in FY25.

The company also confirmed it signed 10 new contracts during the year — nine in the United States and one in Europe — worth $407 million at contracted minimums, alongside six renewals worth a combined $141 million. That takes total new and renewed Business announced for the year to roughly $548 million. Management framed FY26 as its second-biggest year ever for new contract wins, behind only the FY25 haul that included the landmark Trinity Health deal.

The bigger picture

Pro Medicus sells Visage, a cloud-based image-viewing and archiving system that lets radiologists pull up large diagnostic studies almost instantly, typically charged on a per-exam transactional basis. That model is the source of both its margins and its stickiness: once a hospital network migrates, switching is disruptive and the revenue recurs with volume. Management says Visage is now used by around 11% of the US market and sits inside 11 of the top 20 US healthcare institutions — penetration that gives it both reference customers and a long runway into the remaining ~89%.

The next leg is product expansion beyond core radiology. A digital pathology and AI-driven reporting platform is already in production in Europe, and the company flagged a US release of its AI offering in the first half of calendar 2027. Layering pathology and AI onto the same hospital relationships would widen both its addressable market and its per-customer revenue without a proportional lift in cost.

Bull case

The bull thesis is straightforward: a founder-led, debt-free business with ~75% operating margins, a $1.34 billion contracted book growing above 40%, and a demonstrated ability to keep winning marquee US health systems year after year. Each new contract is long-dated and transactional, so revenue tends to build as implementations "come on stream" — many of this year's wins were signed late in the second half and have yet to fully contribute. Add optionality from AI and pathology, and the compounding runway looks intact.

Risks

The obvious risk is valuation. Pro Medicus trades on a multiple that leaves no room for disappointment, which is precisely why the February result — record profit and all — still sparked a slide. Growth is also lumpy: revenue recognition depends on the timing of large implementations, and a stronger Australian dollar can mask genuine operational progress, as it did this year. Reliance on the US market concentrates currency and policy exposure, and the reported profit's dependence on investment gains means headline numbers can swing on markets unrelated to the business.

What investors should watch next

Three things. First, conversion of the $1.34 billion forward book into recognised revenue as FY26's late-signed contracts ramp through FY27. Second, execution on the US AI launch slated for the first half of calendar 2027 and early traction for digital pathology in Europe — the clearest signals of whether Pro Medicus can grow beyond core radiology. Third, the pace of new contract signings: after two consecutive blockbuster years, the market will be watching closely to see whether the pipeline can keep delivering deals of the scale investors have come to expect.